137 related articles for article (PubMed ID: 17458919)
1. Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol).
Bradley DP; Tessier JL; Checkley D; Kuribayashi H; Waterton JC; Kendrew J; Wedge SR
NMR Biomed; 2008 Jan; 21(1):42-52. PubMed ID: 17458919
[TBL] [Abstract][Full Text] [Related]
2. Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat.
Tai JH; Tessier J; Ryan AJ; Hoffman L; Chen X; Lee TY
Neoplasia; 2010 Sep; 12(9):697-707. PubMed ID: 20824046
[TBL] [Abstract][Full Text] [Related]
3. PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.
Rudin M; McSheehy PM; Allegrini PR; Rausch M; Baumann D; Becquet M; Brecht K; Brueggen J; Ferretti S; Schaeffer F; Schnell C; Wood J
NMR Biomed; 2005 Aug; 18(5):308-21. PubMed ID: 15918178
[TBL] [Abstract][Full Text] [Related]
4. Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours.
Checkley D; Tessier JJ; Kendrew J; Waterton JC; Wedge SR
Br J Cancer; 2003 Nov; 89(10):1889-95. PubMed ID: 14612898
[TBL] [Abstract][Full Text] [Related]
5. Quantitative dynamic contrast-enhanced MRI in tumor-bearing rats and mice with inversion recovery TrueFISP and two contrast agents at 4.7 T.
Weidensteiner C; Rausch M; McSheehy PM; Allegrini PR
J Magn Reson Imaging; 2006 Sep; 24(3):646-56. PubMed ID: 16878308
[TBL] [Abstract][Full Text] [Related]
6. Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.
Troiani T; Serkova NJ; Gustafson DL; Henthorn TK; Lockerbie O; Merz A; Long M; Morrow M; Ciardiello F; Eckhardt SG
Clin Cancer Res; 2007 Nov; 13(21):6450-8. PubMed ID: 17975157
[TBL] [Abstract][Full Text] [Related]
7. Decrease in tumor cell oxygen consumption after treatment with vandetanib (ZACTIMA; ZD6474) and its effect on response to radiotherapy.
Ansiaux R; Dewever J; Grégoire V; Feron O; Jordan BF; Gallez B
Radiat Res; 2009 Nov; 172(5):584-91. PubMed ID: 19883226
[TBL] [Abstract][Full Text] [Related]
8. Dynamic Contrast-Enhanced MRI Using a Macromolecular MR Contrast Agent (P792): Evaluation of Antivascular Drug Effect in a Rabbit VX2 Liver Tumor Model.
Park HS; Han JK; Lee JM; Kim YI; Woo S; Yoon JH; Choi JY; Choi BI
Korean J Radiol; 2015; 16(5):1029-37. PubMed ID: 26357497
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
[TBL] [Abstract][Full Text] [Related]
10. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
Gustafson DL; Frederick B; Merz AL; Raben D
Cancer Chemother Pharmacol; 2008 Feb; 61(2):179-88. PubMed ID: 17393165
[TBL] [Abstract][Full Text] [Related]
11. Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).
Siemann DW; Norris CM; Ryan A; Shi W
Anticancer Res; 2009 Jun; 29(6):1987-92. PubMed ID: 19528456
[TBL] [Abstract][Full Text] [Related]
12. Distribution of gadomelitol in a human breast tumor model in mice.
Corot C; Robert P; Lancelot E; Martinell A; Santus R
MAGMA; 2005 Jul; 18(3):138-43. PubMed ID: 16047191
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.
Ciardiello F; Caputo R; Damiano V; Caputo R; Troiani T; Vitagliano D; Carlomagno F; Veneziani BM; Fontanini G; Bianco AR; Tortora G
Clin Cancer Res; 2003 Apr; 9(4):1546-56. PubMed ID: 12684431
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model.
Ceelen W; Smeets P; Backes W; Van Damme N; Boterberg T; Demetter P; Bouckenooghe I; De Visschere M; Peeters M; Pattyn P
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1188-96. PubMed ID: 16457965
[TBL] [Abstract][Full Text] [Related]
15. Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate.
Bradley DP; Tessier JJ; Lacey T; Scott M; Jürgensmeier JM; Odedra R; Mills J; Kilburn L; Wedge SR
Magn Reson Imaging; 2009 Apr; 27(3):377-84. PubMed ID: 18814988
[TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment.
Claes A; Gambarota G; Hamans B; van Tellingen O; Wesseling P; Maass C; Heerschap A; Leenders W
Int J Cancer; 2008 May; 122(9):1981-6. PubMed ID: 18081012
[TBL] [Abstract][Full Text] [Related]
17. Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.
Brave SR; Odedra R; James NH; Smith NR; Marshall GB; Acheson KL; Baker D; Howard Z; Jackson L; Ratcliffe K; Wainwright A; Lovick SC; Hickinson DM; Wilkinson RW; Barry ST; Speake G; Ryan AJ
Int J Oncol; 2011 Jul; 39(1):271-8. PubMed ID: 21537841
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas.
Kummar S; Gutierrez ME; Chen A; Turkbey IB; Allen D; Horneffer YR; Juwara L; Cao L; Yu Y; Kim YS; Trepel J; Chen H; Choyke P; Melillo G; Murgo AJ; Collins J; Doroshow JH
Eur J Cancer; 2011 May; 47(7):997-1005. PubMed ID: 21247755
[TBL] [Abstract][Full Text] [Related]
19. Effects of vandetanib on adenoma formation in a dextran sodium sulphate enhanced Apc(MIN/+) mouse model.
Alferez DG; Ryan AJ; Goodlad RA; Wright NA; Wilkinson RW
Int J Oncol; 2010 Oct; 37(4):767-72. PubMed ID: 20811697
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model.
Gule MK; Chen Y; Sano D; Frederick MJ; Zhou G; Zhao M; Milas ZL; Galer CE; Henderson YC; Jasser SA; Schwartz DL; Bankson JA; Myers JN; Lai SY
Clin Cancer Res; 2011 Apr; 17(8):2281-91. PubMed ID: 21220477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
